The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Bevacizumab, temozolomide, and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly-diagnosed glioblastoma multiforme (GBM).
J. J. Vredenburgh
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
A. Desjardins
No relevant relationships to disclose
D. A. Reardon
Consultant or Advisory Role - Roche/Genentech; Schering-Plough
Honoraria - Roche/Genentech; Schering-Plough
K. Peters
No relevant relationships to disclose
J. Kirkpatrick
Honoraria - BrainLAB; Varian Medical Systems
Research Funding - Genentech; Varian Medical Systems
A. D. Coan
No relevant relationships to disclose
L. Bailey
No relevant relationships to disclose
D. Janney
No relevant relationships to disclose
C. Lu
Employment or Leadership Position - Duke University Medical Center
H. S. Friedman
Consultant or Advisory Role - Genentech
Honoraria - Roche/Genentech